News coverage about Pulmatrix (NASDAQ:PULM) has been trending somewhat positive this week, according to Accern Sentiment. Accern ranks the sentiment of news coverage by analyzing more than 20 million news and blog sources. Accern ranks coverage of publicly-traded companies on a scale of -1 to 1, with scores closest to one being the most favorable. Pulmatrix earned a media sentiment score of 0.21 on Accern’s scale. Accern also assigned media headlines about the biotechnology company an impact score of 44.7534485330033 out of 100, indicating that recent news coverage is somewhat unlikely to have an impact on the stock’s share price in the next few days.
Pulmatrix (NASDAQ:PULM) traded up $0.02 during trading hours on Monday, reaching $1.48. The company’s stock had a trading volume of 178,500 shares, compared to its average volume of 1,715,154. The company has a market capitalization of $29.79, a PE ratio of -1.07 and a beta of 1.68. Pulmatrix has a twelve month low of $0.50 and a twelve month high of $6.98.
Pulmatrix (NASDAQ:PULM) last posted its quarterly earnings results on Thursday, November 9th. The biotechnology company reported ($0.22) EPS for the quarter, beating the Zacks’ consensus estimate of ($0.30) by $0.08. The business had revenue of $0.34 million for the quarter. research analysts anticipate that Pulmatrix will post -0.95 earnings per share for the current fiscal year.
Pulmatrix, Inc is a clinical stage biopharmaceutical company developing inhaled therapies to address serious pulmonary disease. The Company’s product pipeline is focused on advancing treatments for rare diseases, including PUR1900, an inhaled anti-fungal for patients with lung disease, including cystic fibrosis.
Receive News & Ratings for Pulmatrix Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pulmatrix and related companies with MarketBeat.com's FREE daily email newsletter.